VIVUS to Present at the H.C. Wainwright 20th Annual Global Investment Conference on September 5, 2018

CAMPBELL, Calif., Aug. 22, 2018 (GLOBE NEWSWIRE) -- VIVUS, Inc. ( VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that John Amos, Chief Executive Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 5:30 pm ET in New York City. Mr. Amos will provide a corporate overview, review the Company’s clinical and commercial product portfolio, and discuss the company’s strategies for building a portfolio of cash flow-positive assets, reducing its debt and moving toward sustained profitability.

An audio webcast of the presentation will be available in the events and presentations section of the Company’s investor relations website, or by clicking here.

About VIVUS

VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about the Company, please visit www.vivus.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2017 as filed on March 14, 2018, and as amended by the Form 10-K/A filed on April 26, 2018, and periodic reports filed with the Securities and Exchange Commission.